Riskpilot← Back to searchSign inGet full accessResoTher Pharma A/S
A/SActiveCVR 37852406Dronninggårds Alle 136Research and experimental development on natural sciences and engineering · NACE 7210Est. 20165 employees
Revenue 2024
—
EBITDA margin
—
+29% vs 2023
Equity ratio
81.6%
Financial strength
Net profit 2024
DKK -10,1M
+42% vs 2023
| Revenue | — | — |
| EBITDA | DKK -12,8M | +29% |
| Net profit | DKK -10,1M | +42% |
| Total assets | DKK 14,8M | -32% |
| Equity | DKK 12,1M | -42% |
| Employees | 5 | — |
Legal name
ResoTher Pharma A/S
CVR number
37852406
Legal form
Aktieselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
4. juli 2016
Share capital
DKK 571.460
Employees
5 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør og et bestyrelsesmedlem i forening, eller af den samlede bestyrelse.
Company purpose
Selskabet har til formål at gennemføre forskning i og udvikling af peptidbaserede lægemidler rettet mod inflammation, forprogrammeret celledød, cancer samt koagulerings- og blodlegmesygdomme, med særlig fokus på Annexin A1-deriverede peptider; at foretage investeringer i interesser, som gennemfører tilsvarende aktiviteter, herunder i immaterielle rettigheder knyttet til sådanne; og at gennemføre med lægemiddeludvikling relaterede aktiviteter.
Address
Dronninggårds Alle 136
Email
akr@resotherpharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -815 | -2.071 | — | — | — | — | — | — |
| Staff expenses | -211 | -923 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -1.026 | -2.994 | -3.998 | -7.084 | -12.129 | -28.066 | -18.072 | -12.825 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -588 | 4.343 | -1.806 | -0 |
| EBIT | -1.026 | -2.994 | -3.998 | -7.084 | -12.717 | -32.409 | -19.878 | -12.825 |
| Net financials | -0 | -95 | -421 | -497 | -890 | -309 | -13 | -12 |
| Profit before tax | -1.026 | -3.089 | -4.419 | -7.581 | -13.606 | -32.718 | -19.891 | -12.837 |
| Tax | -194 | -677 | -503 | -2.385 | -1.928 | -5.500 | -2.393 | -2.766 |
| Net profit | -832 | -2.413 | -3.916 | -5.196 | -11.678 | -27.218 | -17.498 | -10.071 |
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 1.189 | 1.044 | 5.438 | 4.535 | 41.406 | 18 | 21.761 | 14.847 |
| Equity | 958 | -1.455 | 1.712 | -560 | 38.631 | 12.174 | 20.760 | 12.122 |
| Long-term debt | 0 | 2.171 | 3.001 | 3.677 | 0 | 0 | 0 | 0 |
| Short-term debt | 231 | 327 | 725 | 1.418 | 2.775 | 5.632 | 1.001 | 2.725 |
| Total debt | 231 | 2.499 | 3.726 | 5.095 | 2.775 | 5.632 | 1.001 | 2.725 |
EBITDA margin
-1282500000.0%
This company
15.8%
Market median
-8117088708% vs market
20172024
Equity ratio
81.6%
This company
38.2%
Market median
+114% vs market
20172024
Return on equity
-83.1%
This company
18.4%
Market median
-552% vs market
20172024
Net profit margin
-1007100000.0%
This company
8.1%
Market median
-12433333433% vs market
20172024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20172024
Debt / equity
0.22×
This company
0.62×
Market median
+65% vs market
20172024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2016-07-04 – 2017-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AK Chief Executive Officer | Chief Executive Officer | 2023 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2019 | — | — | |
| Board of Directors | 2017 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2021 | — | — | |
| Chairman | 2025 | — | — | |
| Board of Directors | 2017 | — | — | |
| Board of Directors | 2018 | — | — | |
| Chairman | 2018 | — | — | |
| Board of Directors | 2025 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
TJ Biotech Holding ApS | Company | 5.0% | 5.0% | 2021 |
Quantass ApS | Company | 5.0% | 5.0% | 2021 |
Uddannelses- og Forskningsstyrelsen | Company | 5.0% | 5.0% | 2021 |
Pinnacle Holding ApS | Company | 5.0% | 5.0% | 2019 |
| Individual | 15.0% | 15.0% | 2017 | |
| Individual | 5.0% | 5.0% | 2017 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Quantass ApS
ResoTher Pharma A/S Board members of ResoTher Pharma A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anders Kronborg | Chief Executive Officer | 0 companies |
| Lars Henning Stigel | Board of Directors | 0 companies |
| Henrik Stage | Board of Directors | 0 companies |
| Sven Martin Jacobson | Board of Directors | 0 companies |
| Roderick John Flower | Board of Directors | 0 companies |
| Thomas Feldthus | Board of Directors | 0 companies |
| Rebecca Anne Morison | Chairman | 0 companies |
| Mette Munch | Board of Directors | 0 companies |
| Jeppe Øvli Øvlesen | Board of Directors | 0 companies |
| Kirsten Aarup Drejer | Chairman | 0 companies |
| Thomas Engelbrecht Nordkild Jonassen | Board of Directors | 0 companies |